Related Experiment Video

Updated: Apr 14, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

MET-Mutated NSCLC with Major Response to Crizotinib

Melody A Mendenhall1, Jonathan W Goldman1

  • 1The David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, California.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 23, 2015
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

547
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Related Experiment Videos

Last Updated: Apr 14, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

547
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

Articles linked to this work by shared authors, journal, and citation graph.

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology.

NPJ precision oncology·2026

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.

Lung cancer (Amsterdam, Netherlands)·2026

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

European journal of cancer (Oxford, England : 1990)·2026

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD.

JTO clinical and research reports·2026

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

The New England journal of medicine·2026

Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Weight Gain on Lorlatinib is Associated with Accumulation of Visceral Adipose Tissue.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Identifying the extra nanoparticles from SCR-equipped diesel engines and reducing them via regulating surface tension of aqueous urea solution.

Journal of hazardous materials·2026

Diverse unsaturated fatty acids bypass loss of FabH-catalysed initiation of fatty acid synthesis in Enterococcus faecalis.

Microbiology (Reading, England)·2026

Epigenetic remodeling during UV exposure: high resolution analysis of histone post-translational modifications in a DNA binding protein 2 mutant model.

Histochemistry and cell biology·2026

Diffusion of NiH on Ni(111) and of Ni with Adsorbed H on Ni(111) in the Context of Ni Coarsening in Solid Oxide Cells.

The journal of physical chemistry letters·2026

An Engineered Enzyme Catalyzing Tandem Reductive Aminations for Synthesizing Tertiary Amines.

Angewandte Chemie (International ed. in English)·2026

Origins of Reactivity in SAM-Utilizing Ribozyme SAMURI-Catalyzed RNA Alkylation.

Journal of the American Chemical Society·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us